CompletedNot Applicable

Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia

United States17 participantsStarted 2016-04

Plain-language summary

This study is geared toward characterizing the recovery of brain activity and cognitive function following treatments of electroconvulsive therapy and ketamine general anesthesia.

Who can participate

Age range

18 Years – 60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Treatment resistant depression requiring outpatient ECT * Planned right unilateral ECT stimulation * English speaking * Able to provide written informed consent Exclusion Criteria: * Known brain lesion or neurological illness that causes cognitive impairment * Schizophrenia * Schizoaffective disorder * Blindness or deafness or motor impediments that may impair performance for cognitive testing battery * Inadequate ECT seizure duration with etomidate

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in Cognitive Function During Recovery: Rate of Recovery

Timeframe: 0, 30, 60, 90, 120 minutes following return of consciousness, assessed on treatment days 1-6.

Change in Cognitive Function During Recovery: Initial Decrement

Timeframe: 0, 30, 60, 90, 120 minutes following return of consciousness, assessed on treatment days 1-6.

Trial details

NCT IDNCT02761330

SponsorWashington University School of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-09-11

Results submitted2020-09-11

View on ClinicalTrials.gov More Depression trials

Who can participate

Age range

18 Years – 60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Change in Cognitive Function During Recovery: Rate of Recovery

Timeframe: 0, 30, 60, 90, 120 minutes following return of consciousness, assessed on treatment days 1-6.

Change in Cognitive Function During Recovery: Initial Decrement

Timeframe: 0, 30, 60, 90, 120 minutes following return of consciousness, assessed on treatment days 1-6.